Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Inclusion Criteria: * Body mass index (BMI) \>/= 27 kg/m2 * HbA1c between 7.5% and 10.5% (inclusive) * C-Peptide (fasting) greater than or equal to 500 pmol/L * On stable dose of metformin alone or in combination with a stable dose of sulfonylurea for \>/= 3 months prior to screening, and remain on stable dose throughout the study * Agree to conduct home-based (fasted) blood glucose testing as directed Exclusion Criteria: * Clinically significant abnormalities in medical history or physical exam * Serum creatinine \> ULN at Screening * Clinical signs or symptoms of liver disease, acute or chronic hepatitis, or ALT or AST \> 1.5x ULN at Screening * History of renal transplantation or renal dialysis * GFR \< 60 mL/min at Screening * History of diabetic ketoacidosis * History of greater than 3 episodes of severe hypoglycemia within 6 months of screening * Allergy to sulfur containing drugs * Treatment with other drugs or medications not allowed per study specific Disallowed Concomitant Medicines * Any other significant illness or condition that may interfere with the patient participating or completing the study * Inability or unwillingness to comply with protocol or study procedures